What do systematic reviews say?

Vedolizumab vs placebo

Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.58 [0.49, 0.68]
  1 study · 373 participants
  Moderate

Vedolizumab vs placebo

Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.99 [0.93, 1.07]
  2 studies · 941 participants
  High

Vedolizumab vs placebo

Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 1.01 [0.72, 1.42]
  3 studies · 1122 participants
  Moderate

Etoricoxib vs placebo

Etoricoxib showed no clear difference in exacerbation of IBD compared with placebo (low certainty).

• Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of… 2014 · Cochrane Headline outcomes only
  RR 0.88 [0.45, 1.69]
  1 study · 159 participants
  Low

Bronchial thermoplasty vs active control

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 429 participants
  Moderate

Bronchial thermoplasty vs active control

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 429 participants
  Moderate

Bronchial thermoplasty vs active control

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 409 participants
  GRADE not reported

Bronchial thermoplasty vs active control

Bronchial thermoplasty leads to higher participants admitted to hospital because of respiratory adverse… compared with any active control (high certainty).

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  RR 3.5 [1.26, 9.68]
  3 studies · 429 participants
  High

Bronchial thermoplasty vs active control

Bronchial thermoplasty showed no clear difference in participants admitted to hospital because of respiratory adverse… compared with any active control (moderate certainty).

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  RR 1.12 [0.44, 2.85]
  3 studies · 429 participants
  Moderate

Bronchial thermoplasty vs active control

• Bronchial thermoplasty for moderate or severe persistent asthma in adults 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 429 participants
  Low

Oral iron vs inactive control

It is very uncertain whether oral iron changes mortality compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 1.05 [0.68, 1.61]
  4 studies · 659 participants
  Very low

Parenteral iron vs inactive control

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1629 participants
  Very low

Parenteral iron vs inactive control

It is very uncertain whether parenteral iron changes serious adverse events compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 1 [0.74, 1.34]
  7 studies · 1802 participants
  Very low

Oral iron vs inactive control

It is very uncertain whether oral iron changes proportion requiring blood transfusion compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 0.74 [0.55, 0.99]
  3 studies · 546 participants
  Very low

Oral iron vs inactive control

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 300 participants
  Very low

Oral iron vs inactive control

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 402 participants
  Very low

Oral iron vs inactive control

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 276 participants
  Very low

Oral iron vs inactive control

It is very uncertain whether oral iron changes serious adverse events compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 0.96 [0.76, 1.22]
  5 studies · 731 participants
  Very low

Parenteral iron vs inactive control

It is very uncertain whether parenteral iron changes mortality compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 1.04 [0.63, 1.69]
  10 studies · 2141 participants
  Very low

Parenteral iron vs inactive control

It is very uncertain whether parenteral iron changes proportion requiring blood transfusion compared with inactive control (very low certainty).

• Iron therapy in anaemic adults without chronic kidney disease 2014 · Cochrane Headline outcomes only
  RR 0.84 [0.66, 1.06]
  8 studies · 1315 participants
  Very low